A landmark research revealed June 2, 2026, in JCO Oncology Observe and concurrently introduced on the 2026 American Society of Scientific Oncology Annual Assembly by researchers on the College of Pennsylvania Perelman Faculty of Drugs has produced findings that would reshape how America’s medical neighborhood thinks about GLP-1 receptor agonist medication and the way thousands and thousands of girls with weight problems method their very own most cancers threat.
The research, led by Dr. Elizabeth McDonald, a professor of radiology at Penn and working towards breast radiologist at Penn’s Abramson Most cancers Heart, discovered that girls utilizing GLP-1 medicines have been roughly 30% much less more likely to develop breast most cancers than girls who weren’t taking these medication. The discovering comes from an evaluation of 111,646 girls, the biggest research of its form, and the protecting impact held even after rigorous statistical matching to manage for confounding elements.
The size and rigor of the Penn Drugs research are what elevate it above prior observational work on this space. Researchers used digital well being information from the College of Pennsylvania Well being System, which incorporates each tutorial and neighborhood medical websites throughout Pennsylvania and New Jersey, to establish girls aged 45 to 80 with a BMI of 25 or above who had undergone breast imaging between January 2022 and June 2025.
Of the 111,646 girls within the full cohort, 15,264 (13.7%) had documented GLP-1 medicine prescriptions, and 96,382 (86.3%) had no documented GLP-1 publicity. The researchers examined most cancers incidence in each the total cohort and a matched cohort of 30,528 girls, pairing every GLP-1 consumer one-to-one with a management affected person matched on age, race, ethnicity, BMI, breast density, and diabetes standing.
The outcome: 35.1% decrease odds of breast most cancers within the full evaluation; 30.5% decrease odds within the rigorously matched cohort.
Why the 30% Discount Is Scientifically Credible
The breast most cancers discovering is according to what GLP-1 medication do biologically. GLP-1 receptor agonists, the drug class that features Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide), produce important weight reduction and enhance key metabolic measures equivalent to insulin sensitivity, irritation ranges, and intercourse hormone stability. Every of those adjustments is independently linked to decrease breast most cancers threat by way of well-established organic pathways.
Physique fats isn’t just storage tissue; it’s hormonally lively. It converts androgens into estrogens by way of a course of referred to as aromatization. In postmenopausal girls who’re obese or overweight, fats tissue turns into the primary supply of circulating estrogen. Most breast cancers, about 70 to 75 p.c, are estrogen receptor-positive, that means they develop in response to estrogen. When weight is lowered, fats tissue decreases, aromatization declines, estrogen ranges drop, and the expansion stimulus for these cancers is lowered. This mechanism is broadly accepted and helps clarify why weight problems will increase breast most cancers threat and why weight reduction lowers it.
GLP-1 medication additionally cut back continual low-grade irritation, measured by way of markers equivalent to CRP, which might contribute to a tumor-friendly setting. As well as, they enhance insulin resistance, decreasing ranges of insulin and IGF-1, each of which have been proven to immediately promote breast most cancers cell progress.
“Whereas our research was observational and doesn’t definitively affirm an affiliation,” Dr. McDonald mentioned, “it does add to the rising physique of proof suggesting that it is value investigating these weight-loss medication as potential most cancers prevention instruments.”
The Philadelphia Context: Penn Drugs, Penn’s Abramson Heart, and What This Means Domestically
The Penn Drugs analysis carries explicit significance in Philadelphia, the place the research was performed. The Penn Abramson Most cancers Heart, constantly ranked among the many high most cancers hospitals in the USA, is residence to a significant breast imaging and breast oncology program. The well being system spans Pennsylvania and New Jersey, and the digital well being information used within the research mirror a real-world affected person inhabitants within the higher Philadelphia area, together with a variety of physique weight profiles, most cancers threat elements, and GLP-1 prescribing patterns.
Philadelphia County has a breast most cancers incidence price above the nationwide common, pushed partly by increased weight problems charges amongst girls, particularly in lower-income areas of North, West, and South Philadelphia. If GLP-1 medication cut back breast most cancers threat by 30% in obese and overweight girls, the identical group that accounts for a lot of the county’s burden, the general public well being influence may very well be important. Entry turns into the important thing difficulty. The ladies more than likely to profit are additionally these more than likely to face insurance coverage and value limitations to GLP-1 remedy.
What Ladies Ought to Talk about with Their Docs Now
The Penn Drugs research is observational — it doesn’t show causality and doesn’t represent a scientific advice to prescribe GLP-1 medication for breast most cancers prevention. Breast most cancers prevention at the moment depends on way of life modification, screening adherence, chemoprevention with tamoxifen or aromatase inhibitors for high-risk people, and prophylactic surgical choices for these with BRCA mutations.
What the research does justify is a dialog: girls aged 45 to 80 who’re obese or overweight, who’re contemplating GLP-1 remedy for weight problems or diabetes administration, ought to ask their supplier whether or not the breast most cancers threat knowledge provides weight to the scientific rationale for his or her remedy. For ladies who’re already on GLP-1 medicines, this research supplies further scientific assist for the worth of continued remedy. For oncologists, this knowledge provides a brand new dimension to the affected person dialog about weight administration as most cancers prevention — one with a selected drug class and a quantified threat discount.